Health data may not make your boss ‘app-y
27 January 2015 | By Lukats and Shapiro
Half of UK bosses tempted to snoop on employees health app data to catch them ‘pulling a sickie’...
List view / Grid view
27 January 2015 | By Lukats and Shapiro
Half of UK bosses tempted to snoop on employees health app data to catch them ‘pulling a sickie’...
26 January 2015 | By Lukats and Shapiro
Doctors fear the wealth of health data from the internet and smartphones could be creating a new army of “worried well”, a survey for the Astellas Innovation DebateTM shows...
8 December 2014 | By Astellas
Astellas Pharma Europe Ltd. announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for enzalutamide (trade name XTANDI™)...
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
18 March 2014 | By Astellas
Roxadustat could change treatment of anaemia associated with CKD and remove the need for multiple injections...
29 May 2013 | By Amgen
Innovative joint venture to address unmet medical needs of patients in Japan...
15 May 2013 | By Astellas
Astellas Pharma announces plans to reshape its research framework to further enhance the ability to generate innovative drugs...
15 May 2013 | By Astellas Pharma Inc.
The FDA also approved the cobas® EGFR Mutation Test, which was developed by Roche and validated in the pivotal EURTAC study...
26 April 2013 | By Red Consultancy
Enzalutamide recommended for approval in the European Union (EU)...
14 March 2013 | By Pegasus
The EC has approved expanded options for pre-treatment prior to use of QUTENZA...
10 December 2012 | By Red Consultancy
Results from a completed phase II study...
6 September 2012 | By Abbott
Abbott has signed an agreement to collaborate with Astellas Pharma Global Development...
24 July 2012 | By Pegasus
The first study to compare the 8% capsaicin patch with pregabalin...
4 January 2012 | By Astellas
Tivozanib has demonstrated superiority over sorafenib...
5 September 2011 | By Astellas Pharma Inc.
Astellas will obtain worldwide exclusive rights...